Viewing Study NCT00002639



Ignite Creation Date: 2024-05-05 @ 11:22 AM
Last Modification Date: 2024-10-26 @ 9:03 AM
Study NCT ID: NCT00002639
Status: COMPLETED
Last Update Posted: 2013-06-21
First Post: 1999-11-01

Brief Title: Suramin in Treating Patients With Recurrent Primary Brain Tumors
Sponsor: Emory University
Organization: National Cancer Institute NCI

Study Overview

Official Title: ANALYSIS OF THE EFFICACY OF SURAMIN IN RECURRENT MALIGNANT PRIMARY BRAIN TUMORS
Status: COMPLETED
Status Verified Date: 2001-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

PURPOSE Phase II trial to study the effectiveness of suramin in treating patients with recurrent primary brain tumors following radiation therapy
Detailed Description: OBJECTIVES I Estimate the efficacy of suramin in patients with recurrent primary brain tumors as measured by radiographic response time to progression and survival II Assess the toxic effects of suramin in this patient population

OUTLINE Single-Agent Chemotherapy Suramin SUR NSC-34936

PROJECTED ACCRUAL If at least 1 of the first 14 patients experiences at least a partial response a total of 25 patients will be entered over approximately 30 months

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
EUC-DON-9420 None None None
NCI-T94-0033O None None None